• Founded: 2020
  • Location: Cambridge, MA
  • Employee range: 50 - 200
  • Clinical stage: Clin0
  • Therapy area: Diabetes (1)
  • Drug types: IMM, END, HEP, LNG
  • Lead product: GNTI-122
  • Product link:
  • Funding: $157M Aug 2021; $20M A Aug 2020
  • Investors: OrbiMed, Novartis Venture Fund, RA Capital Management

job board

Short description:

Engineered regulatory T cells

Drug notes:

3+ undisclosed programs RD primary biliary cholangitis, viral ARDS, undisclosed

Long description:

GentiBio is developing engineered regulatory T cells (Tregs). Tregs are the body’s natural means for keeping the immune system in balance. Tregs suppress potentially pathogenic immune activation and promote tissue repair; however, Treg activity is lost in some diseases. GentiBio is using their modular engineering platform to create optimized Tregs as powerful and tailored therapeutics for autoimmune and inflammatory diseases. GentiBio’s engineered Tregs overcome the limitations of endogenous, sorted Tregs by transforming the cells with superior phenotypes including resistance to inflammation, increased potency and scalable manufacturing. GentiBio’s most advanced product is GNTI-122, an autologous engineered Tregs product to treat type 1 diabetes.


Scientist I/II, Discovery
Cambridge, MAOn-site|18 days ago

© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy